MGNX MacroGenics Inc.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in February 2023:

  • Guggenheim Healthcare Talks | Oncology Day (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Thursday, February 9, 2023, at 2:45 pm ET.  MacroGenics’ management will also participate in one-on-one meetings.
  • SVB Securities Global Biopharma Conference (Virtual). Scott Koenig, M.D., Ph.D., will participate in a formal presentation session with a SVB Securities research analyst on Tuesday, February 14, 2023, at 3:00 pm ET.  MacroGenics’ management will also participate in one-on-one meetings.

A webcast of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at /events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.   

About MacroGenics, Inc.



MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###



CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,   
EN
06/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

 PRESS RELEASE

MacroGenics Provides Update on Corporate Progress and Third Quarter 20...

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an updat...

 PRESS RELEASE

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences: BMO Biopharma Spotlight Series: Oncology Day Date: Wednesday, November 8, 2023 Fireside Chat: 10:30 am ET Location: VirtualStifel 2023 Healthcare Conference Date: Tuesday, Novembe...

 PRESS RELEASE

MacroGenics Announces Date of Third Quarter 2023 Financial Results Con...

MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, November ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 4, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch